Hyperpigmentation — whether from sun damage, hormonal changes (melasma), or post-inflammatory marks from acne — is one of the most common reasons people visit a dermatologist. For decades, hydroquinone at 2 to 4 percent was the gold standard treatment. It works by inhibiting tyrosinase, the enzyme that catalyses the first step in melanin synthesis. However, prolonged use carries risks including paradoxical darkening (ochronosis), contact dermatitis, and potential cytotoxicity to melanocytes themselves.
Melaslow is a newer-generation tyrosinase inhibitor that achieves comparable melanin reduction through a different mechanism. Rather than destroying melanocytes, it modulates the enzymatic pathway upstream, reducing the amount of melanin each cell produces while leaving the cell intact. At a 5 percent concentration, clinical trials demonstrated a statistically significant reduction in melanin index after 28 days of twice-daily application, with continued improvement through week eight.
Genevia's Evita Bright Lotion combines Melaslow 5% with Niacinamide (Vitamin B3), which inhibits the transfer of melanosomes from melanocytes to surrounding keratinocytes — a complementary pathway that addresses pigmentation at a different stage. The dual-action approach means the skin produces less melanin and distributes less of what it does produce, leading to a more even-toned complexion without the bleached appearance that aggressive depigmenting agents can cause.
The formulation is particularly relevant for Fitzpatrick skin types III through VI, where hyperpigmentation is more prevalent and more resistant to treatment. These skin types also carry the highest risk of hydroquinone-induced ochronosis, making Melaslow a safer alternative for long-term maintenance. Evita Bright is dermatologically tested, non-comedogenic, and suitable for use on the face, neck, and backs of hands — the areas most prone to UV-induced dark spots.
For optimal results, brightening treatment should always be paired with rigorous sun protection. UV exposure stimulates melanogenesis directly, undermining any depigmenting regimen. Dermatologists recommend applying a broad-spectrum SPF 50 sunscreen every morning — even on cloudy days — when using any tyrosinase inhibitor. Genevia's Solar Sun Lotion was designed as a companion product for exactly this purpose.